Honokiol applied to human head and neck (HNSCC), buccal cavity (SCC-1), larynx (SCC-5), tongue (OSC-19), and pharynx (FaDu) cancer cell lines inhibited cell viability through induction of apoptosis, correction of dysregulated G0/G1 phase cell cycle proteins, and reduction of the expression of epidermal growth factor receptor (EGFR) and mTOR. Here, EGFR is linked to cancer.